Opendata, web and dolomites

FIBROHALT

Advancing a novel peptide-based therapeutic for pancreatic cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FIBROHALT project word cloud

Explore the words cloud of the FIBROHALT project. It provides you a very rough idea of what is the project "FIBROHALT" about.

licensing    pharmaceutical    opportunity    clear    treatment    aggressive    enhanced    patient    consists    models    prakash    clinically    optimal    potentially    clinical    regression    dr    fda    metselaar    diseases    ema    ceo    forms    founder    biopharmaceutical    pursuing    add    university    bart    de    stromal    scientific    xenograft    av3    chemotherapies    peptide    reduces    80    team    breakthrough    mission    company    efficacy    chemotherapy    stage    fibrohalt    disease    twente    inventor    grow    strategy    stroma    approvals    devastating    barrier    medical    pancreatic    create    sell    rate    pioneering    cancers    dismal    fibrous    pursue    obtain    perform    strategies    coo    fibrosis    spun    promotes    intensively    drug    overview    50    gt    median    matrix    market    position    entrepreneur    form    jai    join    distant    survival    metastasis    stimulate    explanation    co    unmet    2016    prognosis    deal    demonstrated    developer    drugs    neighbouring    plan    treat       cells    prof    tumor    risk    cancer   

Project "FIBROHALT" data sheet

The following table provides information about the project.

Coordinator
SCARTEC THERAPEUTICS BV 

Organization address
address: DE HORST 2 ZUIDHORST 254
city: ENSCHEDE
postcode: 7522 LW
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://prakash-lab.com/people/prakash/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCARTEC THERAPEUTICS BV NL (ENSCHEDE) coordinator 50˙000.00

Map

 Project objective

Pancreatic cancer is a devastating disease with a median 5-year survival rate of 3-5%. One explanation for the dismal prognosis is the failure of many chemotherapies. Pancreatic tumor cells stimulate neighbouring non-tumor cells (stromal cells) to join and grow around them. This stroma forms a fibrous matrix that promotes 1) aggressive tumor growth, 2) distant metastasis, and 3) form a barrier to chemotherapy and drug delivery. There is a high need to enhance the success of pancreatic cancer treatment by intensively pursuing strategies that target the tumor stroma. We are developing a novel peptide-based drug (AV3), that targets and reduces tumor stroma in pancreatic cancer, and potentially in other fibrosis-associated cancers. We have demonstrated that AV3 reduces fibrosis (>50%) and enhanced the efficacy of chemotherapy in clinically relevant patient-derived xenograft models (achieving up to 80% tumor regression). Thus, our novel peptide has the potential to become a breakthrough add-on to chemotherapy in the treatment of pancreatic cancer. We are a biopharmaceutical company, spun-out in 2016 by the University of Twente. Our mission is to develop novel, targeted, peptide-based drugs to treat pancreatic cancer and other fibrosis-associated cancers and diseases with high unmet medical needs. The management team consists of its pioneering scientific founder and inventor of the technology Prof. Jai Prakash (CEO) and an experienced entrepreneur and drug developer Dr. Bart Metselaar (COO). The FIBROHALT project will (1) create a clear overview of the clinical opportunity for AV3 in pancreatic cancer, 2) develop a strategy to position the drug in the pancreatic cancer market, and (3) create an optimal development strategy, including a de-risk plan for future clinical studies. We will pursue a co-development or licensing deal for AV3 with a pharmaceutical company which will perform late-stage clinical development, obtain EMA/FDA approvals, market and sell AV3.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FIBROHALT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FIBROHALT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More